Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months

CMAJ

Volumn 187, Issue 7, 2015, Pages E215-E223

  McQuaid, Fiona ^a,b   Snape, Matthew D ^a,b   John, Tessa M ^a,b   Kelly, Sarah ^a,b   Robinson, Hannah ^a,b   Yu, Ly Mee ^a   Toneatto, Daniela ^c   D'Agostino, Diego ^d   Dull, Peter M ^e   Pollard, Andrew J ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

^c NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^d Research and Development   (Netherlands)

^e Novartis Vaccines and Diagnostics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; MENINGOCOCCUS VACCINE; 4CMENB VACCINE;

ABDOMINAL PAIN; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTHRALGIA; ARTICLE; BACTERIAL STRAIN; CHILD; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ERYTHEMA; FEMALE; FEVER; HEADACHE; HEMATURIA; HUMAN; INFANCY; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE REACTION; IRRITABILITY; MALE; MENINGOCOCCOSIS; NAUSEA; OPEN STUDY; PAIN; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RASH; SOMNOLENCE; SWELLING; TONSILLITIS; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION; VACCINATION; VOMITING; ADAPTIVE IMMUNITY; IMMUNOLOGY; NEISSERIA MENINGITIDIS; PRESCHOOL CHILD; SERUM BACTERICIDAL ANTIBODY ASSAY; TIME;

ADAPTIVE IMMUNITY; ANTIBODIES, BACTERIAL; CHILD, PRESCHOOL; FEMALE; HUMANS; MALE; MENINGOCOCCAL VACCINES; NEISSERIA MENINGITIDIS, SEROGROUP B; SERUM BACTERICIDAL ANTIBODY ASSAY; TIME FACTORS;

EID: 84928492165     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.141200     Document Type: Article

References (17)

1. Andrews SM, Pollard AJ. A vaccine against serogroup B Neisseria meningitidis: dealing with uncertainty. Lancet Infect Dis 2014;14:426-34.
2. Ladhani SN, Flood JS, Ramsay ME, et al. Invasive meningococcal disease in England and Wales: implications for the introduction of new vaccines. Vaccine 2012;30:3710-6.
3. Viner RM, Booy R, Johnson H, et al. Outcomes of invasive meningococcal serogroup B disease in children and adolescents (MOSAIC): a case-control study. Lancet Neurol 2012;11:774-83.
4. Invasive meningococcal disease (laboratory reports in England):2013/2014 annual data by epidemiological year. Health Prot Rep 2015;9(3):1-3. Available: www.gov. uk/government/uploads/system/uploads/attachment-data/file/397913/hpr0315-imd.pdf (accessed 2015 Feb. 21).
5. Pan-Canadian Public Health Network. The recommended use of the multicomponent meningococcal B (4CMenB) vaccine in Canada. Ottawa: Public Health Agency of Canada; 2014. Available: www.phac-aspc.gc.ca/naci-ccni/mening-4cmenb-exec-resum-eng.php (accessed 2014 Nov. 22).
6. Minutes of the meeting on Tuesday 11 and Wednesday 12 February 2014. Joint Committee on Vaccination and Immunisation; 2014. Available: www.gov. uk/government/groups/joint-committee-on-vaccination-and-immunisation#minutes (accessed 2014 Nov. 22).
7. Findlow J, Borrow R, Snape MD, et al. Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. Clin Infect Dis 2010;51:1127-37.
8. Toneatto D, Ismaili S, Ypma E, et al. The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans. Hum Vaccin 2011;7:646-53.
9. Snape MD, Saroey P, John TM, et al. Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose. CMAJ 2013;185:E715-24.
10. Martin NG, Snape MD. A multicomponent serogroup B meningococcal vaccine is licensed for use in Europe: What do we know, and what are we yet to learn? Expert Rev Vaccines 2013;12:837-58.
11. Borrow R, Carlone GM, Rosenstein N, et al. Neisseria meningitidis group B correlates of protection and assay standardization - international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005. Vaccine 2006;24:5093-107.
12. JCVI position statement on the use of Bexsero® meningococcal B vaccine in the UK. London (UK): Department of Health and Public Health England; 2014. Available: www.gov. uk/government/publications/meningococcal-b-vaccine-jcvi-position-statement (accessed 2014 Nov. 22).
13. Snape MD, Dawson T, Oster P, et al. Immunogenicity of two investigational serogroup B meningococcal vaccines in the first year of life: a randomized comparative trial. Pediatr Infect Dis J 2010;29:e71-9.
14. Santolaya ME, O'Ryan M, Valenzuela MT, et al. Persistence of antibodies in adolescents 18-24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine. Hum Vaccin Immunother 2013;9:2304-10.
15. Frosi G, Biolchi A, Lo Sapio M, et al. Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. Vaccine 2013;31:4968-74.
16. Bettinger JA, Scheifele DW, Halperin SA, et al. Diversity of Canadian meningococcal serogroup B isolates and estimated coverage by an investigational meningococcal serogroup B vaccine (4CMenB). Vaccine 2013;32:124-30.
17. Targeted meningococcal serogroup B vaccination campaign in the Saguenay-Lac-Saint-Jean. Quebec City: Santé et Services sociaux Québec; 2014. Available: www.msss.gouv. qc.ca/sujets/santepub/vaccination/index.php?meningococcal-b-vaccination-campaign (accessed 2015 Feb. 21).